AP-26113 (Brigatinib)

• Catalog#: C-1031
  
• Targets: ALK; EGFR
• Synonym: AP-26113; AP26113; AP 26113, Brigatinib
• Chemical Name/IUPAC:(2-((5-chloro-2-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide
• SMILES Code: CN1CCN(C2CCN(C3=CC=C(NC4=NC=C(Cl)C(NC5=CC=CC=C5P(C)(C)=O)=N4)C(OC)=C3)CC2)CC1

Technical Data

• Product Name: AP-26113 (Brigatinib)
• Chemical Formula: C29H39ClN7O2P
• Moleculer Weight: 584.1
• CAS#: 1197953-54-0
• Appearance: Solid powder
• Purity: > 99% by HPLC
• Solubility: Soluble in DMSO
• Storage: Room temperature for months, or -20ºC for 3 years

Description

AP-26113 (Brigatinib) is an orally active, potent and selective dual ALK/EGFR inhibitor. AP-26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP-26113 appears to overcome mutation-based resistance.